CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE
ESSAIS TESTANT LE ROLE DE LA CHIMIOTHERAPIE SEQUENTIELLE


Précédent Retour au menu principal  Suivant


référence

chimiothérapie

n

(stIV)

% RO

p

SM

p

Edelman,

2004 (1)

I. Carboplatine + gemcitabine puis paclitaxel

95

80 %

21

 

9 m

 

II. Cisplatine + vinorelbine puis docétaxel

83

85 %

28

9 m

Sculier,

2007(2)

Cisplatine + gemcitabine + ifosfamide (GIP) x 3 cycles ; if no progression

485

 

36

 

 

0,17

I. GIP

140

127

 

9,7 m

II. paclitaxel

141

126

 

11,9 m

Grigorescu,

2007 (3)

I. Gemci + vinorelbine x 2 puis Ifo-gemci x 2

50

48 %

8

0,019

6,5 m

0,16

II. Gemci + cisplatine (70)

52

44 %

25

9,7 m

Vergnenègre,

2009 (4) I

Cisplatine (75) + gemcitabine 2 cycles : si non progression

228

 

 

 

 

 

I. Cisplatine (75) + gemcitabine

45

96 %

16 %

 

11 m

NS

II  paclitaxel + gemcitabine

42

98 %

21 %

10,7 m

 



Références


(1) Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR et al. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 2004; 10(15):5022-5026.

(2) Sculier J, Lafitte J, Lecomte J, Alexopoulos C, Van CO, Giner V, et al. A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer. Ann Oncol 2007 Jun;18(6):1037-42.

(3) Grigorescu A, Ciuleanu T, Firoiu E, Muresan DR, Teodorescu G, Basson BR. A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC). Lung Cancer 2007 Aug;57(2):168-74.

(4) Vergnenegre A, Tillon J, Corre R, Barlesi F, Berard H, Vernejoux JM, et al. A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin-gemcitabine chemotherapy (GFPC 03-01 Study). J Thorac Oncol 2009 Mar;4(3):364-70.


Retour au début de la page